Furthermore, SLC2A3, SLC2A6, SLC2A9, SLC2A12, and SLC2A14 levels were lower in patients with advanced tumor stages, suggesting that these genes might act as a barrier to the progression of LUAD. This evidence concerns the gene SLC2A14 and neoplasm.